Evidence map›Paper›PMID 20309761›Full record

ArticleJournal of biopharmaceutical statistics2010

Genotype-based risk and pharmacogenetic sampling in clinical trials.

Nicholas J Schork, Eric J Topol

Open access · greenAbstract read
In one paragraph

Article in Journal of biopharmaceutical statistics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Genotype-Based Recall Studies in Complex Cardiometabolic Traits.Circulation. Genomic and precision medicine · 2018
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nicholas J SchorkScripps Translational Science Institute and Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA. nschork@scripps.edu
Eric J Topol
Scripps Research Institute · US

Funding

Systems BiologyU19AG023122 · NIA · TRANSLATIONAL GENOMICS RESEARCH INST · PI Ryan Tewhey · 2004 to 2026
$102.6M
SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE (UL1)UL1RR025774 · NCRR · SCRIPPS RESEARCH INSTITUTE, THE · PI TOPOL, ERIC JEFFREY · 2008 to 2011
$16.3M
Substance Abuse & Behavioral Disinhibition: Integrating Genes & EnvironmentU01DA024417 · NIDA · UNIVERSITY OF MINNESOTA · PI IACONO, WILLIAM G. · 2007 to 2010
$10.8M
TARGETING GENETIC PATHWAYS FOR BRAIN OVERGROWTH IN AUTISM SPECTRUM DISORDERSP50MH081755 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI COURCHESNE, ERIC · 2007 to 2013
$10.3M
Genomic Association Study of Bipolar DisorderR01MH078151 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KELSOE, JOHN R. · 2007 to 2009
$5.5M
The Bipolar Genome StudyR01MH094483 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CRAIG, DAVID W, EDENBERG, HOWARD J · 2012 to 2014
$2.2M
CNS HIV ANTI-RETROVIRAL THERAPY EFFECTS RESEARCH /CHARTER/ -278022005-278022005N01MH022005 · NIMH · UNIVERSITY OF CA -SAN DIEGO · PI GRANT, IGOR · 2003 to 2006
–
NCRR NIH HHS U54 RR0252204-01NCRR NIH HHS UL1 RR025774NIA NIH HHS U19 AG023122NIA NIH HHS U19 AG023122-01NIDA NIH HHS U01 DA024417NIMH NIH HHS 1 R01 MH078151-01A1NIMH NIH HHS N01 MH022005NIMH NIH HHS P50 MH081755NIMH NIH HHS P50 MH081755-01NIMH NIH HHS R01 MH078151NIMH NIH HHS R01 MH094483
6 · The paper itself

Abstract

A number of recent genome-wide association (GWA) studies have identified unequivocal statistical associations between inherited genetic variations, mostly single-nucleotide polymorphisms (SNPs), and common complex diseases such as diabetes, cardiovascular disease, and obesity. Genotyping individuals for these variations has the potential to help redefine how pharmacologic agents undergo clinical development. By identifying carriers of known genomic variants that contribute to susceptibility, a high-risk population can be defined, as well as individuals with potential for a better response to a drug. We evaluated the potential utility that selecting individuals for a trial on the basis of genotypes identified in contemporary GWA studies would have had on recently described clinical trials. We pursued this by constraining both the risks of a disease outcome associated with particular genotypes and overall drug responses to those actually observed in genetic association and clinical trial studies, respectively. We pursued these evaluations in the context of clinical trials investigating drugs for macular degeneration, obesity, heart disease, type II diabetes, prostate cancer, and Alzheimer's disease. We show that the increase in incidence of outcomes in trials restricted to individuals with specific genotypic profiles can result in substantial reductions in requisite sample sizes for such trials. In addition, we also derive realistic bounds for samples sizes for clinical trials investigating pharmacogenetic effects that leverage genetic variations identified in recent association studies.

Indexed as

Models, StatisticalAlzheimer DiseaseClinical Trials as TopicData Interpretation, StatisticalDiabetes Mellitus, Type 2FemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHeart DiseasesHumansMacular DegenerationMaleObesityPharmacogeneticsPhenotypePolymorphism, Single Nucleotide

Identifiers

PMID20309761
PMCPMC2892229
OpenAlexW2006136956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.